The group plans to use the method to analyze isoform differences of B cell surface receptors, common targets for immunotherapy.
The researchers are testing the method in a clinical trial of hospital-acquired pneumonia and are working on tests for meningitis and prosthetic joint infections.
The Menlo Park, California-based company plans to demonstrate its sequencing technology on a small genome in the near future.
The company plans to use the funding to build beta units of its optical nanopore sequencer for early adopters in industry and academia.
The Beijing-based firm said it will use the funding for research and development, to obtain additional intellectual property, and to pursue its strategic goals.
The company had £13.8 million ($18.4 million) in revenues and a net loss of £56.6 million in 2017.
University of Oxford researchers used DNA scaffolds to build custom peptide nanopores that they said could make nanopore-based protein analysis more feasible.
CTO Clive Brown provided an overview of the new approach during a presentation at the firm's user meeting last week.
Using a protocol developed at the University of Oxford, the researchers hope that nanopore sequencing can aid diagnosis and drug resistance profiling in remote areas.
Under the terms of the agreement, Oxford Nanopore Technologies will not sell its 2D sequencing products in the UK and in Germany for five years.
The UK's Human Fertility and Embryology Authority calls for consumer genetic testing companies to warn customers that testing could uncover family secrets, according to the Guardian.
The New York Times reports that United Nations delegates have been discussing how to govern the genetic resources of the deep sea.
Researchers have transplanted edited cells into mice that appear to combat cocaine addiction, New Scientist reports.
In PNAS this week: analysis of proteolytic enzymes secreted by circulating tumor cells, phylogenetic study of Fv1 evolution, and more.